newsfilter
← Latest News
GlobeNewswire·

Galera Announces FDA Acceptance and Priority Review of Avasopasem NDA for Radiotherapy-Induced Severe Oral Mucositis

PDUFA target date of August 9, 2023 Avasopasem would be first drug approved for SOM in patients with head and neck cancer MALVERN, Pa., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (NASDAQ:GRTX),